Precision-Guided Therapy Selection
Predict likelihood of durable anti-TNF response prior to initiating therapy
Up to 30% of patients who start an anti-TNF do not respond1
and up to 50% lose response in the first year2
Lack of individualized therapeutic selection tools:
•Reduced therapeutic
• Potential loss of response
• Inefficient care
• Negative impact on quality of life
Guide therapeutic selection with a serogenomic test
Respondr™, available exclusively from Prometheus Laboratories, predicts an individual patient’s likelihood of anti-TNF response prior to treatment initiation to support therapy selection and patient management decisions and to help get patients in remission faster
Intrinsic clearance and genetics are prognostic factors that impact biologic response
- Intrinsic clearance is a pharmacokinetic variable prior to drug exposure that predicts metabolism/elimination of a biologic.
- The HLADQA1*05 G allele is associated with increased risk of antidrug antibody formation, loss of response, and anti-TNF discontinuation3,4
- The combination of intrinsic clearance (>0.326 L/day) and genetics identify patients at an increased risk of poor anti-TNF response, immunogenicity, and inadequate disease control5
Respondr TNF is a laboratory-developed test that was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and is performed exclusively in our high complexity CLIA-certified (05D0917432) and College of American Pathologists-accredited (6805501) clinical laboratory. As laboratory a developed test, it has not been cleared or approved by the US FDA. This test is not yet available for patients in NY-State. This test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.
References
- Aitken et al. IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. A Review of 2017 and Outlook to 2022. April 2018.
- Syed et al. Crohn’s & Colitis 360. 2020;2:otaa050.
- Sazonovs et al. Gastroenterology. 2020;158:189-199.
- Wilson et al. Aliment Pharmacol Ther. 2020;51:356-363.
- Spencer et al. Front Immunol. 2024;15:doi:10.3389/fimmu.2024.1342477.